Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.19 – $14.85
85% from low
Exchange
OTC Link
ADRC
Borrow rate
5.58%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.59B | $43.55B | $41.40B | $44.08B | $50.74B | $47.64B | $46.61B | $43.78B |
| Cost of revenue | $17.01B | $17.47B | $19.14B | $16.82B | $19.87B | $19.75B | $21.27B | $17.86B |
| Gross profit | $22.58B | $26.08B | $22.26B | $27.27B | $30.87B | $27.89B | $25.34B | $25.92B |
| Gross margin | 57.0% | 59.9% | 53.8% | 61.9% | 60.8% | 58.5% | 54.4% | 59.2% |
| R&D | $5.25B | $5.34B | $7.13B | $5.41B | $6.57B | $5.37B | $6.21B | $5.54B |
| Operating income | $3.91B | $5.04B | −$2.94B | $6.97B | $6.26B | −$150.0M | $3.33B | $6.68B |
| EBITDA | $6.26B | $8.77B | −$11.48B | $6.97B | $10.44B | $4.21B | $8.81B | $10.57B |
| Net income | $1.70B | $2.43B | −$15.56B | $1.00B | $4.15B | −$2.94B | −$2.55B | −$3.48B |
| Net margin | 4.3% | 5.6% | -37.6% | 2.3% | 8.2% | -6.2% | -5.5% | -7.9% |
| EPS (diluted) | 0.45 | 0.62 | -3.96 | 0.26 | 1.06 | -0.75 | -0.65 | -0.88 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $46.4B | $1.11 | $1.08–$1.13 | 2 |
| 2027 | $47.5B | $1.18 | $1.09–$1.24 | 2 |
| 2028 | $48.9B | $1.32 | $1.30–$1.34 | 1 |
| 2029 | $49.9B | $1.35 | $1.33–$1.38 | 1 |
Forward consensus · source: Financial Modeling Prep
BAYER AG S/ADR
No one on the platform currently holds BAYRY.
No tracked institution reports a position in BAYRY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-28 | $0.0321 | 2026-05-11 |
| 2025-04-29 | $0.0311 | 2025-05-12 |
| 2024-04-29 | $0.0294 | 2024-05-13 |
| Execution date | Ratio |
|---|---|
| 2017-09-20 | 4-for-1 |
No one on the platform has traded BAYRY yet.
| $13.4B |
| — |
| JDHIFJD Health International Inc. | $5.85 | +0.00% | $18.7B | — |
| ORINYOrion Oyj | $41.27 | +9.09% | $23.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
You can still file a late claim in the $38M Bayer ($BAYRY /$BAYERCROP.NSE ) investor settlement. The settlement claims that Bayer misled investors about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. After several jury verdicts raised concerns about the company's exposure, $BAYRY / $BAYERCROP.NSE declined and investors filed suit. Investors who held $BAYRY / $BAYERCROP.NSE shares between 2016 and 2020 may still be eligible to file a claim: https://11th.com/cases/bayer-investor-settlement
View on StockTwits ↗$BAYRY sure would love to see this thing test it's 14.50s 52 week high again 🥹 Most likely we see chop until settlement approval hearing on July 9th
View on StockTwits ↗$AMAT +9.7% $GLW +9.1% $BAYRY +16% $CAT +5.81% https://truthsandnews.com/markets/top-stock-gainers-today-june-25-2026
View on StockTwits ↗$BAYRY this made up for my other laggers today... Still holding.... Honest trajectory back to the 30s and 40s if not more.... Too much good activity at this company to ignore with this behemoth
View on StockTwits ↗$BAYRY Jeah, perfect timing with my trades on this one!!
View on StockTwits ↗$BAYRY it's out y'all, big winner 👍 https://www.supremecourt.gov/opinions/25pdf/24-1068_n7ip.pdf
View on StockTwits ↗$BAYRY $LLY | Eli Lilly And Bayer Hit Out At Germany’s Spending On New Medicines - FT https://www.ft.com/content/1c2ba206-6111-464c-98e9-711741e33037?shareType=nongift
View on StockTwits ↗$BAYRY looks like SCOTUS is done for the day. Onwards to Thursday's opinion day! 😬
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 1.2× sales vs its 1.1× historical median P/S.
Fair value ≈ $13.24 · price $13.70 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.